Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.
The pipeline guide provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape.
It provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy, complete with analysis by stage of development, drug target, mechanism of action, route of administration and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
The guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR) .
- The pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Proliferative Vitreoretinopathy (PVR) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Proliferative Vitreoretinopathy (PVR) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR)
Key Topics Covered:
Proliferative Vitreoretinopathy (PVR) – Overview
Proliferative Vitreoretinopathy (PVR) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Proliferative Vitreoretinopathy (PVR) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Proliferative Vitreoretinopathy (PVR) – Companies Involved in Therapeutics Development
- Aldeyra Therapeutics Inc
- Aptitude Medical Systems Inc
- Focal Point Pharmaceuticals Inc
- Novartis AG
- Panag Pharma Inc
- Ractigen Therapeutics Inc
Proliferative Vitreoretinopathy (PVR) – Drug Profiles
- Aptamers to Inhibit PDGF for Proliferative Vitreoretinopathy – Drug Profile
- methotrexate – Drug Profile
- OM-101 – Drug Profile
- onternabez – Drug Profile
- RAG-1C – Drug Profile
- Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy – Drug Profile
- XOMA-089 – Drug Profile
Proliferative Vitreoretinopathy (PVR) – Dormant Projects
Proliferative Vitreoretinopathy (PVR) – Product Development Milestones
List of Tables
- Number of Products under Development for Proliferative Vitreoretinopathy (PVR), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Proliferative Vitreoretinopathy (PVR) – Pipeline by Aldeyra Therapeutics Inc, 2022
- Proliferative Vitreoretinopathy (PVR) – Pipeline by Aptitude Medical Systems Inc, 2022
- Proliferative Vitreoretinopathy (PVR) – Pipeline by Focal Point Pharmaceuticals Inc, 2022
- Proliferative Vitreoretinopathy (PVR) – Pipeline by Novartis AG, 2022
- Proliferative Vitreoretinopathy (PVR) – Pipeline by Panag Pharma Inc, 2022
- Proliferative Vitreoretinopathy (PVR) – Pipeline by Ractigen Therapeutics Inc, 2022
Proliferative Vitreoretinopathy (PVR) – Dormant Projects, 2022
List of Figures
- Number of Products under Development for Proliferative Vitreoretinopathy (PVR), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned
- Aldeyra Therapeutics Inc
- Aptitude Medical Systems Inc
- Focal Point Pharmaceuticals Inc
- Novartis AG
- Panag Pharma Inc
- Ractigen Therapeutics Inc
For more information about this report visit https://www.researchandmarkets.com/r/4c4a50
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
